Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 343-347

  Wingard, J R ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ABLC; Bone marrow transplant; Lipid complex; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CREATININE;

ARTICLE; BONE MARROW TRANSPLANTATION; CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEVER; FUNGICIDAL ACTIVITY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RISK;

EID: 0031057798     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700664     Document Type: Article

References (18)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Vaughn WP. Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies. Semin Oncol 1993; 20: 55-58.
3. Atkinson K. Bone marrow transplantation. Med J Aust 1992; 157: 408-411.
4. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17(Suppl. 6): 10-13.
5. Milliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990: 12 (Suppl. 3): S374-S379.
6. Walsh TJ, Rubin M, Hathorn J et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. Arch Intern Med 1991: 151: 765-770.
7. Bodey GP. The emergence of fungi as major hospital pathogens. J Hasp Infect 1988; 11 (Suppl. A): 411-426.
8. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-688.
9. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990; 88: 5-22N-5-27N.
10. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 (Suppl. 1): S43-S53.
11. Sabra R, Branch RA. Amphotericin-B nephrotoxicity. Drug Safety 1990; 5: 94-108.
12. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
13. Janoff AS, Boni LT, Popescu MC et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988; 85: 6122-6126.
14. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993; 3: 451-471.
15. Perkins WR, Minchey SR, Boni LT et al. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992: 1107: 271-282.
16. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 4-7 October 1994, Orlando, Florida. Abstr. No. M69, p 247.
17. Anaissie EJ, White M Uzun O et al. Amphotericin B lipid complex vs amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 18 September 1995, San Francisco, California. Abstr. No. LM21. p 330.
18. Hiemenz JW, Lister LW, Anaissie EJ et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995; 86: Abstr. 3383.